🔴 Kura Oncology is trading 9% down today — no confirmed company-specific explanation

Kura Oncology is trading 8.83% lower at $8.84, with no confirmed company-specific explanation for the drop.

• It is down from the November 3 close of $9.88, despite broad U.S. markets and biotech moving higher.
• Kura announced November 4 presentations of eight ziftomenib abstracts at the upcoming ASH meeting, including first FLT3-combination data; reports do not link the announcement to the decline.
• Third-quarter results are scheduled for November 10; the date change was announced November 3.